| Code | CSB-RA010144MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to CDX014, targeting HAVCR1 (Hepatitis A Virus Cellular Receptor 1), also known as TIM-1 or KIM-1. HAVCR1 functions as a phosphatidylserine receptor involved in the clearance of apoptotic cells and regulation of immune responses. This type I membrane protein plays significant roles in T cell activation, tolerance, and autoimmunity. HAVCR1 is markedly upregulated in kidney injury and serves as a biomarker for acute kidney injury and renal cell carcinoma. Additionally, aberrant expression has been associated with various malignancies and immune-mediated diseases, making it an important target for therapeutic and diagnostic research.
CDX014 is a humanized anti-HAVCR1 monoclonal antibody originally developed for antibody-drug conjugate applications in oncology, particularly targeting renal cell carcinoma where HAVCR1 shows elevated expression on tumor cells. This biosimilar antibody provides researchers with a reliable tool for investigating HAVCR1 biology, exploring its role in cancer progression, kidney pathology, and immune regulation, as well as supporting preclinical studies in oncology and nephrology research.
There are currently no reviews for this product.